Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Adjunctive treatment with brexpiprazole and escitalopram reduces behavioral stress responses and increase hypothalamic NPY immunoreactivity in a rat model of PTSD-like symptoms.

Cohen H, Zohar J, Kaplan Z, Arnt J.

Eur Neuropsychopharmacol. 2018 Jan;28(1):63-74. doi: 10.1016/j.euroneuro.2017.11.017. Epub 2017 Dec 8.

PMID:
29224968
2.

The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks.

van den Munkhof HE, Arnt J, Celada P, Artigas F.

Eur Neuropsychopharmacol. 2017 Dec;27(12):1248-1257. doi: 10.1016/j.euroneuro.2017.10.034. Epub 2017 Nov 8.

PMID:
29128144
3.

Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission.

Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N.

CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17.

PMID:
28417559
4.

Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.

Milienne-Petiot M, Geyer MA, Arnt J, Young JW.

Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028. doi: 10.1007/s00213-017-4543-7. Epub 2017 Feb 3.

5.

Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats.

Mombereau C, Arnt J, Mørk A.

Pharmacol Biochem Behav. 2017 Feb;153:141-146. doi: 10.1016/j.pbb.2016.12.015. Epub 2017 Jan 3.

PMID:
28057524
6.

Discriminative stimulus properties of 1.25mg/kg clozapine in rats: Mediation by serotonin 5-HT2 and dopamine D4 receptors.

Prus AJ, Wise LE, Pehrson AL, Philibin SD, Bang-Andersen B, Arnt J, Porter JH.

Brain Res. 2016 Oct 1;1648(Pt A):298-305. doi: 10.1016/j.brainres.2016.08.004. Epub 2016 Aug 5.

PMID:
27502027
7.

Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.

Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T.

J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19.

PMID:
24947465
8.

Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.

Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T.

J Pharmacol Exp Ther. 2014 Sep;350(3):605-14. doi: 10.1124/jpet.114.213819. Epub 2014 Jun 19. Erratum in: J Pharmacol Exp Ther. 2014 Dec;351(3):686-7.

PMID:
24947464
9.

Characterization of [³H]Lu AE60157 ([³H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine₆ (5-HT₆) receptors in vivo.

Witten L, Bang-Andersen B, Nielsen SM, Miller S, Christoffersen CT, Stensbøl TB, Brennum LT, Arnt J.

Eur J Pharmacol. 2012 Feb 15;676(1-3):6-11. doi: 10.1016/j.ejphar.2011.11.029. Epub 2011 Dec 4.

PMID:
22155399
10.

Serotonin 2A receptor antagonists for treatment of schizophrenia.

Ebdrup BH, Rasmussen H, Arnt J, Glenthøj B.

Expert Opin Investig Drugs. 2011 Sep;20(9):1211-23. doi: 10.1517/13543784.2011.601738. Epub 2011 Jul 8. Review.

PMID:
21740279
11.

Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.

Di Clemente A, Franchi C, Orrù A, Arnt J, Cervo L.

Addict Biol. 2012 Mar;17(2):274-86. doi: 10.1111/j.1369-1600.2011.00319.x. Epub 2011 Apr 26.

PMID:
21521422
12.

5-HT6 receptor ligands and their antipsychotic potential.

Arnt J, Olsen CK.

Int Rev Neurobiol. 2011;96:141-61. doi: 10.1016/B978-0-12-385902-0.00006-1. Review. No abstract available.

PMID:
21329787
13.

Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Carli M, Calcagno E, Mainini E, Arnt J, Invernizzi RW.

Psychopharmacology (Berl). 2011 Apr;214(3):625-37. doi: 10.1007/s00213-010-2066-6. Epub 2010 Nov 4.

PMID:
21049266
14.

Clozapine and N-methyl-D-aspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice.

Vunck SA, Wiebelhaus JM, Arnt J, Porter JH.

Eur J Pharmacol. 2011 Jan 15;650(2-3):579-85. doi: 10.1016/j.ejphar.2010.10.022. Epub 2010 Oct 20.

PMID:
20969851
15.

Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole.

Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A.

Psychopharmacology (Berl). 2010 Oct;212(3):329-44. doi: 10.1007/s00213-010-1954-0. Epub 2010 Jul 23.

PMID:
20652539
16.

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23.

PMID:
20569520
17.

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.

Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J.

Psychopharmacology (Berl). 2010 Jan;208(1):23-36. doi: 10.1007/s00213-009-1702-5. Epub 2009 Oct 23.

PMID:
19851757
18.
19.

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.

Etievant A, Bétry C, Arnt J, Haddjeri N.

Neurosci Lett. 2009 Aug 21;460(1):82-6. doi: 10.1016/j.neulet.2009.05.035. Epub 2009 May 18.

PMID:
19450663
20.

Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.

Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N.

J Psychopharmacol. 2009 Mar;23(2):177-89. doi: 10.1177/0269881108089586. Epub 2008 May 30.

PMID:
18515444
21.

Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics.

Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J.

Neuropsychopharmacology. 2008 Oct;33(11):2657-66. Epub 2007 Dec 19.

22.

Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.

Hertel P, Didriksen M, Pouzet B, Brennum LT, Søby KK, Larsen AK, Christoffersen CT, Ramirez T, Marcus MM, Svensson TH, Di Matteo V, Esposito E, Bang-Andersen B, Arnt J.

Eur J Pharmacol. 2007 Nov 14;573(1-3):148-60. Epub 2007 Jul 4.

PMID:
17689529
23.

Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Didriksen M, Skarsfeldt T, Arnt J.

Psychopharmacology (Berl). 2007 Aug;193(2):225-33. Epub 2007 Apr 4.

PMID:
17406859
24.

Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat--similar mechanism of action?

Flagstad P, Arnt J, Olsen CK.

Eur J Pharmacol. 2006 Aug 21;544(1-3):69-76. Epub 2006 Jun 28.

PMID:
16860313
25.

Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment.

Didriksen M, Kreilgaard M, Arnt J.

Eur J Pharmacol. 2006 Aug 7;542(1-3):108-15. Epub 2006 May 20.

PMID:
16806167
26.

Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade.

Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mørk A, Honig G, Bøgesø KP, Westerink BH, den Boer H, Wikstrom HV, Tecott LH.

Neuropsychopharmacology. 2004 Oct;29(10):1782-9.

28.
29.

Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.

Pouzet B, Didriksen M, Arnt J.

Pharmacol Biochem Behav. 2002 Apr;71(4):655-65.

PMID:
11888557
30.

Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia.

Pouzet B, Didriksen M, Arnt J.

Pharmacol Biochem Behav. 2002 Apr;71(4):635-43.

PMID:
11888555
31.

Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity.

Hertel P, Byskov L, Didriksen M, Arnt J.

Eur J Pharmacol. 2001 Jun 22;422(1-3):77-81.

PMID:
11430916
32.

In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics.

Sánchez C, Arnt J.

Behav Pharmacol. 2000 Jun;11(3-4):291-8.

PMID:
11103883
34.

Pharmacological differentiation of classical and novel antipsychotics.

Arnt J.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S7-14. Review.

PMID:
9690964
35.

In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro.

Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J.

Psychopharmacology (Berl). 1998 Jun;137(3):233-40.

PMID:
9683000
36.

The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents.

Sánchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J.

J Pharmacol Exp Ther. 1997 Dec;283(3):1323-32. Erratum in: J Pharmacol Exp Ther 1998 May;285(2):929.

PMID:
9400007
37.

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.

Arnt J, Skarsfeldt T.

Neuropsychopharmacology. 1998 Feb;18(2):63-101. Review.

38.

Differentiation of classical and novel antipsychotics using animal models.

Arnt J, Skarsfeldt T, Hyttel J.

Int Clin Psychopharmacol. 1997 Feb;12 Suppl 1:S9-17. Review.

PMID:
9179639
39.

Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models.

Sánchez C, Arnt J, Moltzen E.

Eur J Pharmacol. 1996 Nov 21;315(3):245-54.

PMID:
8982661
41.

The antiaggressive potency of (-)-penbutolol involves both 5-HT1A and 5-HT1B receptors and beta-adrenoceptors.

Sánchez C, Arnt J, Moltzen EK.

Eur J Pharmacol. 1996 Feb 15;297(1-2):1-8.

PMID:
8851159
42.

Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.

Bøgesø KP, Arnt J, Frederiksen K, Hansen HO, Hyttel J, Pedersen H.

J Med Chem. 1995 Oct 27;38(22):4380-92.

PMID:
7473566
43.

Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity.

Arnt J, Sánchez C, Lenz SM, Madsen U, Krogsgaard-Larsen P.

Eur J Pharmacol. 1995 Oct 24;285(3):289-97.

PMID:
8575516
45.

The effects of the new antipsychotic, sertindole, on latent inhibition in rats.

Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J.

Behav Pharmacol. 1994 Apr;5(2):119-124.

PMID:
11224259
46.

Stereospecific and selective 5-HT2 antagonism in a series of 5-substituted trans-1-piperazino-3-phenylindans.

Bøgesø KP, Arnt J, Hyttel J, Pedersen H.

J Med Chem. 1993 Sep 17;36(19):2761-70.

PMID:
8410990
47.

The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice.

Sánchez C, Arnt J, Hyttel J, Moltzen EK.

Psychopharmacology (Berl). 1993;110(1-2):53-59.

PMID:
7870899
48.

Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles.

Andersen K, Perregaard J, Arnt J, Nielsen JB, Begtrup M.

J Med Chem. 1992 Dec 25;35(26):4823-31.

PMID:
1336054

Supplemental Content

Support Center